Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 2/20 | 0.46 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18751674 | 0.91 | CES1 (0.46) | CA2CAMK2AMAPK1LMNAKDM4E | |
| SCHEMBL9791592 | 0.85 | CA2 (0.54) | CA2CAMK2AESR1FNTAFNTB | |
| SCHEMBL16722805 | 0.84 | ELANE (0.52) | CA2CAMK2AESR1ESR2LMNA | |
| SCHEMBL18116111 | 0.83 | CA2 (0.56) | CA2CAMK2ABLMLMNAKDM4E | |
| SCHEMBL11389533 | 0.83 | HPGD (0.55) | CTBP2NPC1RAB9ALMNA | |
| SCHEMBL16706518 | 0.82 | CA2 (0.50) | CA2CAMK2AESR1FNTAFNTB | |
| SCHEMBL14254882 | 0.81 | KDM4E (0.54) | MAPK1CTBP2RAB9ALMNAKDM4E | |
| SCHEMBL21087159 | 0.81 | LOXL2 (0.46) | CA2KDM4E | |
| SCHEMBL18116103 | 0.81 | EPHX2 (0.44) | CA2BLMESRRGLMNA | |
| SCHEMBL8235929 | 0.81 | KMT2A (0.46) | NPC1RAB9ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908866-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170283395-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670180-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-5558978-A | Photoresist compositions containing copolymers having acid-labile groups and recurring units derived from either N-(hydroxymethyl)maleimide or N-(acetoxymethyl)maleimide or both | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0659781-A2 | Copolymers of maleimide, for photoresists | OCG Microelectronic Materials Inc. (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CA2 1547/4885CAMK2A 3063/4885ESR1 2915/4885 |
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | PDXK, DCK, CHEK1 | CA2 740/4885CAMK2A 577/4885ESR1 2806/4885 |
| US-20170283395-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | PDXK, DCK, CHEK1 | CA2 740/4885CAMK2A 577/4885ESR1 2806/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | CA2 2549/4885CAMK2A 4708/4885ESR1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.